Novel VEGFR2 Inhibitors with Thiazoloquinoxaline Scaffold Targeting Hepatocellular Carcinoma with Lower Cardiotoxic Impact

Ten novel thiazoloquinoxaline derivatives coupled with different sulfonamide moieties were designed and synthesized fulfilling pharmacophoric features of vascular endothelial growth factor receptor (VEGFR)-2 inhibition.